STUDIO dei pazienti Off Label
Grafico 19 Pz in tp con Adalimubab
0% 20% 40% 60% 80% 100% 120%
EA Infettivi EA Allergici Inefficacia Switch Interruzione
%
% Tp Fondo % Steroide
Concludendo :
? La perdita di efficacia % è più alta nei pazienti AR piuttosto
che SPS-, indipendentemente dalla terapia di fondo.
? La % di interruzione, nelle 2 malattie, è la stessa
indipendentemente dal trattamento con steroidi e terapia di fondo.
? Gli EA infettivi sono sovrapponibili nelle 2 patologie mentre
una maggiore % di EA allergici si riscontrano in AR.
? La % di interruzione in AR e SPS- è sovrapponibile e
relativamente bassa (~ 5%) rispetto ai dati di letteratura94,95.
? Anche nell’ ambito dell’ AR, non si riscontrano differenze
significative nella % di interruzione, indipendentemente dal trattamento con Ifx o con Etanercept ( ~ 3%).
? I nostri dati dunque confermano l’ efficacia e la tollerabilità a
RIFERIMENTI BIBLIOGRAFICI
1
Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population Sample: results of a regional community-based study. I. The mapping study. Clin Exp Rheumatol 2005;23:819-28
2
Salaffi F, Carotti M, Stancati A, Grassi W. L’ artrite reumatoide: diagnosi precoce, trattamento farmacologico e monitoraggio della terapia. Acta Biomed, 2006; 77; quaderno 3:3-25
3
Quarta E, Eziopatogenesi dell’ artrite reumatoide
http://www.farmaSalute.it/percorsi/Reumatologia/artrite.asp
4
Grassi W, Salaffi F, Filippucci E. Ultrasound in reumatology. Best Pract Res Clin Rheumatol 2005; 19:467-85
5
Salaffi F, Carotti M, Manganelli P, Filippucci E, Giuseppetti GM, Grassi W. Contrast-enhanced power Doppler sonography of Knee sinovitis in rheumatoid artritis: assessment of therapeotic response. Clin Rheumatol 2004;23: 285-90
6
Carotti M, Salaffi F, Manganelli P, Salvolini L, Bichi Secchi E, De Bernardinis S.L’interessamento polmonare sub-clinico nell’artrite reumatoide:studio mediante tomografia ad alta risoluzione. Reumatismo 2001; 53: 280-8.
7
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
8
Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21 (5 Suppl 31): S154-7.
9
Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61:290-7.
10
Salaffi F, Ferraccioli G, Peroni M et al. Progression of erosion and join space narrowing scorse in rheumatoid arthritis assessed by nonlinear models. J Rheumatol.1994;21:1626-30.
11
Visser H,le Cessies S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357-65.
12
Salaffi F, Carotti M, Stancati A, Grassi W. L’ artrite reumatoide: diagnosi precoce, trattamento farmacologico e monitoraggio della terapia. Acta Biomed, 2006; 77; quaderno 3:3-25
13
Felson DT, Anderson JJ, Boers A, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trias. Arthritis Rheum 1993; 36: 729-40. 14
Prevoo MLL, van Riel PLCM, van t’ HofMA et al. Validità and reliability of joint indices. A longitudinal study in patient with recent onset rheumatoid arthritis. Br J Rheumatol 1993; 32: 589-94
15
van Gestel AM, Prevoo MLL, van t’ HofMA et al. The developoment and validation of the Europian League Against Rheumatism response criteria in rheumatoid arthritis. A comparison with the preliminary
American College of Rheumatology and a the WHO/ international
League Against Rheumatism criteria. Arthritis Rheum 1996; 39:34-40
16
Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthitis. Arthritis Rheum 1981; 24: 1308-15.
17
Ferraccioli G. Biologic therapy with anti TNF-alpha in Rheumatoid Arthritis. Reumatismo 2005;57 (Suppl 1): 17-21.
18
Salaffi F, Carotti M, Stancati A, Grassi W. L’ artrite reumatoide: diagnosi precoce, trattamento farmacologico e monitoraggio della terapia. Acta Biomed, 2006; 77; quaderno 3:3-25
19
Valesini G. Are there differences among anti-TNF-alfa biological drugs? Reumatismo, 2005; 57 - N. 4 (Suppl. 1):1-2
20
Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM, et al. Biology of TACE inhibition. Ann Rheum Dis 2001; 60: iii25-iii32.
21
Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade: Europ. Cytokine Netw 1996; 7: 93-124.
22
Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-23.
23
Cui X, Hawari F, AlSaaty S, Lawrence M, Combs CA, et al. Identification of ARTS-1 as a novel TNFR1-bindingbprotein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002; 110: 515-26.
24
Robak T, Gladalska A, Stepien H The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 145-54.
25
Barrera P, Joosten RA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti- tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001; 7: 660-6.
26
Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 (5 Suppl 35): S108-14.
27
Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF Ann Rheum Dis 2003; 62(Suppl 2): ii37-ii42
28
van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004; 22 (5 Suppl 35): S115-21.
29
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
30
Salfeld JG. Use of new biotechnology to design rational drugs against newly defined targets. Best Pract Res Clin Rheumatol 2004; 18: 81-95.
31
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghray EBJ. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane
TNF-a and activates immune effector functions. Cytokine 1995; 7: 251- 9.
32
Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado- Sanchez B, Cuevas-Orta E, Moreno-Valdes R, et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005; 141: 372-80.
33
Scallon BJ, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
34
Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, LebSack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000; 34: 161-4.
35
Granneman RG, Zhang Y, Noertersheuser PA, Velagapudi RB, Awni WM, Locke CS. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA™ ) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. ACR Annual Scientific Meeting; November 2003; Orlando, FL. Poster 256.
36
St.Clair EW, Wagner CL., FaSanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The Relationship of Serum Ifx Concentrations to Clinical Improvement in Rheumatoid Arthritis Results From ATTRACT, a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheum 2002; 46: 1451-9.
37
Zhou H. Unaltered etanercept pharmacokinetics with concurrent mtx in patients with Rheumatoid arthritis J Cl Pharm 2004; 44: 1235-1243.
38
Fiocco U, Bombardieri S, Differences in pharmacology of tumor necrosis factor (TNF) antagonists Reumatismo, 2005; 57 - N. 4 (Suppl. 1):8-16
39
Bathon JM, Martin RW, Fleishmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and mtx in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
40
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog et al. Anti-tumor necrosis factor (TNF)-alpha therapy (etanercept) downregulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41: 484-9.
41
Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277-90.
42
Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-8.
43
Ettinger R, Cerrero H, Wilsom M, Lipsky PE. TNF blockade results in an increase of CD20+ CD27+ (memory) B cells in the peripheral circulation of rheumatoid arthritis (RA) patients. ACR 2002, poster n. 304.
44
Kavanaugh A, Keystone EC. The Safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S203-8.
45
Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001; 60: 133-9.
46
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
47
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
48
Barone D, Krantz c, lambert D, Maggiora K, Mohler K. Comparative analysis of the ability of etanercept and ifx to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum 1999; 42 (Suppl.): S90.
49
Straub RH, Sarzi-Puttini P, Atzeni F, Buttgereit F, Scholmerich J, Cutolo M. Anti-tumour necrosis factor antibody therapy does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increased androstenedione relative to cortisol. Ann Rheum Dis 2005; 64:1353-6.
50
Valesini G, Cutolo M, Effects of TNF antagonists on immune and neuroendocrine system Reumatismo, 2005; 57 - N. 4 (Suppl. 1):3-7
51
Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on Safety. J Rheumatol Suppl 2002; 65: 33-8.
52
Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti- tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on Safety. Ann Rheum Dis 2004; 63: 1538-43.
53
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a populationbased study. Arthritis Rheum 2002; 46: 2287- 93.
54
Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, ifx, and lnf in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
55
Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Care Res 2002; 47: 17-21.
56
Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-21.
57
Matteson EL. Need for circumspection in prescribing tumor necrosis factor nhibitors and other biologic response modifiers. Arthritis Care Res 2002; 47: 1-4.
58
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. The effect of mtx and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
59
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti- tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22.
60
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti- tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22.
61
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7
62
Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653-6.
63
Ferraccioli GF, Gremese E. Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis 2004; 63: 613-5.
64
Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63: 1075-8.
65
FDA Safety update on TNF antagonists, 15/8/2001, pag. 11.
66
US Food and Drug Administration. Safety update on TNF-alfa antagonist: ifx and etanercept.
http://www.fda.gov/ohrms/dokets/ac/01/biefing/3779b2_01_cber_Safety %20_revision2pdf.
67
van der Laken CJ, Lems WF, van Soesbergen RM, van der Sande JJ, Dijkmans BA. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum 2003; 48: 269-70.
68
Marotte H, Charrin JE, Miossec P. Ifx-induced aseptic meningitis. Lancet 2001; 358: 1784.
69
ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of ifx. BMJ 2003; 326: 579.
70
Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson’s disease in rheumatoid arthritis patient treated with ifx. Rheumatology (Oxford) 2003; 42: 702-3.
71
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478- 86.
72
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant mtx: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
73
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Ifx and mtx in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
74
Chung ES, Packer M, Lo KH, FaSanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of ifx, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate- to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
75
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty- six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
76
Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003; 71: 396-8.
77
US Food and Drug Administration. Safety update on TNF-alfa antagonist: ifx and etanercept.
http://www.fda.gov/ohrms/dokets/ac/01/biefing/3779b 2_01_cber_Safety%20_revision2pdf
78
Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of ifx therapy. Arthritis Rheum 2004; 50: 372-79.
79
Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004; 50: 1703-6.
80
Padovan M, MasSara A, Rizzo N, Lo Monaco A, Fotinidi M, La Corte R, et al. Dati di Safety del trattamento con anti-TNFa in una coorte di
183 pazienti affetti da artrite reumatoide, artrite psoriasica e spondilite anchiloSante. Reumatismo 2004; 56 (suppl 2): 388
81
Khanna D, McMahon M, Furst DE. Safety of tumor necrosisfactor- alpha antagonists. Drug Saf 2004; 27: 307-24.
82
Schwartzman S, Morgan GJjr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004; 6 (suppl 2): S19-23.
83
Trotta F, Valentini G, Safety of anti-TNFalfa biological drugs Reumatismo, 2005; 57 - N. 4 (Suppl. 1):34-39
84
R. Gorla, Sopondiloartriti siero negative
http://www.artriti.it/spondiliti/artritisieronegative.html
85
Sieper J; Braun J; Rudwaleit M; Boonen A; Zink A – Ankylosing spondylitis: an overview - Ann Rheum Dis 2002 Dec;61 Suppl 3:1108- 18
86
. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA–B27 positive and negative blood donors. Arthritis Rheum 1998;41:58–67
87
Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D - Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system - Arthritis Rheum 2003 Apr;48(4):1126-36
88
Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61 Suppl 3:iii40–50.
89
Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246–50.
90
Gladman DD, Rahman P, in Ruddy S, Harris ED Jr, Sledge CB et al (eds), Kelley’s Textbook of Rheumatology. Vol 2. 6th ed. New York, NY: WB Saunders Co, 2001, pp 1071-1079
91
Gladman DD. Clinical aspects of the spondyloarthropathies. Am J Med Sci 1998;316:234–8
92
Gladman D. Effectiveness of Psoriatic Arthritis Therapies. Semin Arthritis Rheum 2003; 33:29-37
93
. P J Mease, C E Antoni. Psoriatic arthritis treatment: biological response modifiers Ann Rheum Dis 2005;64(Suppl II):ii78–ii82
94
Cohen G, Courvoisier N , Cohen J.D, Zaltni S, Sany J, Combe B The efficiency of switching from infliximab to etanercept
and vice-versa in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 2005; 23: 795-800.
95
Karen E. Hansen, Julie P. Hildebrand, Mark C. Genovese, John J. Cush, Supen Patel, David A. Cooley, Stanley B. Cohen, Ronald E. Gangnon, And Michael H. Schiff The Efficacy of switching from Etanercept To Infliximab in patients with Rheumatoid Arthritis. The Journal Of Rheumatology 2004; 31:6.